HOUSTON, July 28, 2021 /PRNewswire/ -- Marker
Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage
immuno-oncology company specializing in the development of
next-generation T cell-based immunotherapies for the treatment of
hematological malignancies and solid tumor indications, today
announced that the Company's new cGMP manufacturing facility in
Houston, TX, located near the
George Bush Intercontinental Airport, is fully operational. The
facility will manufacture Marker's MultiTAA-specific T cell
products for the Company's Phase 2 acute myeloid leukemia (AML)
trial as well as future hematological and solid tumor trials, in
addition to producing the potential commercial supply of any
approved products.
"We are excited to open Marker's new in-house cGMP manufacturing
facility and potentially bring our therapies to the affected
patient communities," said Anthony H.
Kim, Chief Financial Officer of Marker Therapeutics.
"Cell therapy manufacturing is a complex science and is a
competitive advantage for Marker. Building our own cGMP
manufacturing facility was a strategic goal for Marker to ensure
broad access to our therapies while reducing overall manufacturing
costs."
The Company employed modular processes to build its cGMP
manufacturing facility at its 48,500 square foot location.
Currently, about a third of the square footage is being utilized
and is dedicated to support the Company's Phase 2 AML trial, which
is expected to enroll 160 patients. Additional clean rooms may be
added using the cost-effective and scalable modular processes for
the manufacturing of other MultiTAA-specific T cell products in
future clinical trials.
About Marker Therapeutics, Inc.
Marker Therapeutics,
Inc. is a clinical-stage immuno-oncology company specializing in
the development of next-generation T cell-based immunotherapies for
the treatment of hematological malignancies and solid tumor
indications. Marker's cell therapy technology is based on the
selective expansion of non-engineered, tumor-specific T cells that
recognize tumor associated antigens (i.e. tumor targets) and kill
tumor cells expressing those targets. This population of T cells is
designed to attack multiple tumor targets following infusion into
patients and to activate the patient's immune system to produce
broad spectrum anti-tumor activity. Because Marker does not
genetically engineer its T cell therapies, we believe that our
product candidates will be easier and less expensive to
manufacture, with reduced toxicities, compared to current
engineered CAR-T and TCR-based approaches, and may provide patients
with meaningful clinical benefit. As a result, Marker believes its
portfolio of T cell therapies has a compelling product profile, as
compared to current gene-modified CAR-T and TCR-based
therapies.
To receive future press releases via email, please visit:
https://www.markertherapeutics.com/email-alerts.
Forward-Looking Statements
This release contains
forward-looking statements for purposes of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Statements in this news release concerning the Company's
expectations, plans, business outlook or future performance, and
any other statements concerning assumptions made or expectations as
to any future events, conditions, performance or other matters, are
"forward-looking statements." Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things:
our research, development and regulatory activities and
expectations relating to our non-engineered multi-tumor antigen
specific T cell therapies; the effectiveness of these programs or
the possible range of application and potential curative effects
and safety in the treatment of diseases; the potential
commercialization of our current and future product candidates; our
manufacturing processes and the cost thereof; and our ability to
use our cGMP manufacturing facility to support clinical and
commercial demand. Forward-looking statements are by their nature
subject to risks, uncertainties and other factors which could cause
actual results to differ materially from those stated in such
statements. Such risks, uncertainties and factors include, but are
not limited to the risks set forth in the Company's most recent
Form 10-K, 10-Q and other SEC filings which are available through
EDGAR at www.sec.gov. Such risks and uncertainties may be amplified
by the COVID-19 pandemic and its impact on our business and the
global economy. The Company assumes no obligation to update our
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/marker-therapeutics-announces-opening-of-new-cgmp-manufacturing-facility-301343458.html
SOURCE Marker Therapeutics, Inc.